SynAct Pharma
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
SYNACT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008241491 (+1 more)
- LEI:
- 549300RRYIEFEQ72N546
- Country:
- Sweden
- Address:
- Scheelevägen 2, 223 63 Lund
- Website:
- https://synactpharma.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
SynAct Pharma is a clinical-stage biotechnology company dedicated to developing innovative treatments for inflammatory and autoimmune diseases. The company's core focus is on resolution therapy, an approach designed to resolve ongoing inflammatory processes rather than merely inhibiting them. Its lead compound, resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors to help the body restore immune balance. By targeting the resolution of inflammation, SynAct Pharma aims to reduce disease progression and offer a new standard of care across a wide spectrum of inflammatory conditions, with a key focus on diseases such as rheumatoid arthritis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-29 07:45 |
Share Issue/Capital Change
Förslag till beslut om bemyndigande för styrelsen att besluta om förvärv och öv…
|
Swedish | 55.9 KB | ||
| 2025-09-29 07:45 |
Pre-Annual General Meeting Information
Proposal for a resolution on authorization for the Board of Directors to resolv…
|
English | 56.5 KB | ||
| 2025-09-16 08:45 |
Board/Management Information
SynAct Pharma’s CFO Björn Westberg leaves for new leading position
|
English | 53.7 KB | ||
| 2025-09-16 08:45 |
Board/Management Information
SynAct Pharmas CFO Björn Westberg slutar för ny ledande befattning
|
Swedish | 53.4 KB | ||
| 2025-08-29 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
|
Swedish | 58.9 KB | ||
| 2025-08-29 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in SynAct Pharma AB
|
English | 58.9 KB | ||
| 2025-08-20 07:30 |
Interim Report
|
Swedish | 6.6 MB | ||
| 2025-08-20 07:30 |
Interim Report
|
English | 6.6 MB | ||
| 2025-08-15 08:55 |
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter en andra konvertering av teckningsoptioner
|
Swedish | 62.1 KB | ||
| 2025-08-15 08:55 |
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after second conversion of warrants
|
English | 61.3 KB | ||
| 2025-08-05 11:34 |
Major Shareholding Notification
|
Swedish | 10.6 KB | ||
| 2025-07-31 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
|
Swedish | 59.6 KB | ||
| 2025-07-31 18:00 |
Share Issue/Capital Change
Change in number of shares and votes in SynAct Pharma AB
|
English | 59.3 KB | ||
| 2025-07-15 22:13 |
Share Issue/Capital Change
Correction: SynAct to receive SEK 17.7 million after conversion of warrants
|
English | 61.8 KB | ||
| 2025-07-15 22:13 |
Share Issue/Capital Change
Rättelse: SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
|
Swedish | 62.8 KB |
Automate Your Workflow. Get a real-time feed of all SynAct Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for SynAct Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-02-24 | Henrik Stage | Other | Sell | 19,000 | 991,345.00 SEK |
| 2021-02-18 | John Haurum | Other | Sell | 5,968 | 328,749.67 SEK |
| 2021-01-06 | Thomas Jonassen | Other | Other | 1,456,263 | N/A |
| 2020-07-22 | Thomas Jonassen | Other | Other | 29,840 | 199,928.00 SEK |
| 2020-07-10 | Jeppe Øvlesen | Other | Other | 29,840 | 199,928.00 SEK |
| 2020-07-09 | John Haurum | Other | Other | 29,840 | 199,928.00 SEK |
| 2020-07-07 | Henrik Stage | Other | Other | 29,840 | 199,928.00 SEK |
